Literature DB >> 24785432

Mucins and tumor resistance to chemotherapeutic drugs.

Nicolas Jonckheere1, Nicolas Skrypek2, Isabelle Van Seuningen2.   

Abstract

Epithelial cancer patients not considered eligible for surgical resection frequently benefit from chemotherapy. Chemotherapy is the treatment of cancer with one or combination of cytotoxic or cytostatic drugs. Recent advances in chemotherapy allowed a great number of cancer patients to receive treatment with significant results. Unfortunately, resistance to chemotherapeutic drug treatment is a major challenge for clinicians in the majority of epithelial cancers because it is responsible for the inefficiency of therapies. Mucins belong to a heterogeneous group of large O-glycoproteins that can be either secreted or membrane-bound. Implications of mucins have been described in relation to cancer cell behavior and cell signaling pathways associated with epithelial tumorigenesis. Because of the frequent alteration of the pattern of mucin expression in cancers as well as their structural and functional characteristics, mucins are thought to also be involved in response to therapies. In this report, we review the roles of mucins in chemoresistance and the associated underlying molecular mechanisms (physical barrier, resistance to apoptosis, drug metabolism, cell stemness, epithelial-mesenchymal transition) and discuss the therapeutic tools/strategies and/or prognosis biomarkers for personalized chemotherapy that could be proposed from these studies.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cancer; Chemotherapeutic drug; Mucin; Prognosis biomarker; Resistance

Mesh:

Substances:

Year:  2014        PMID: 24785432     DOI: 10.1016/j.bbcan.2014.04.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  31 in total

1.  MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling.

Authors:  I Lakshmanan; S Rachagani; R Hauke; S R Krishn; S Paknikar; P Seshacharyulu; S Karmakar; R K Nimmakayala; G Kaushik; S L Johansson; G B Carey; M P Ponnusamy; S Kaur; S K Batra; A K Ganti
Journal:  Oncogene       Date:  2016-01-11       Impact factor: 9.867

Review 2.  Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Authors:  Muzafar A Macha; Shiv Ram Krishn; Rahat Jahan; Kasturi Banerjee; Surinder K Batra; Maneesh Jain
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

3.  Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.

Authors:  Anna Astashchanka; Thomas M Shroka; Britta M Jacobsen
Journal:  Breast Cancer Res Treat       Date:  2018-10-13       Impact factor: 4.872

4.  Molecular Pathways: Mucins and Drug Delivery in Cancer.

Authors:  Chinthalapally V Rao; Naveena B Janakiram; Altaf Mohammed
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

5.  Mucin-producing hamster cholangiocarcinoma cell line, Ham-2, possesses the aggressive cancer phenotypes with liver and lung metastases.

Authors:  Piyanard Boonnate; Kulthida Vaeteewoottacharn; Ryusho Kariya; Sawako Fujikawa; Thidarut Boonmars; Somchai Pinlaor; Chawalit Pairojkul; Seiji Okada
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-09-21       Impact factor: 2.416

6.  Is mucin a determinant of peritoneal dissemination of gastrointestinal cancer? Analysis of mucin depletion in two preclinical models.

Authors:  S Masoumi-Moghaddam; A Amini; D L Morris
Journal:  Clin Transl Oncol       Date:  2016-05-19       Impact factor: 3.405

7.  Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; Winston Liauw; David Lawson Morris
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

8.  Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway.

Authors:  Rahat Jahan; Muzafar A Macha; Satyanarayana Rachagani; Srustidhar Das; Lynette M Smith; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-16       Impact factor: 5.187

9.  Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.

Authors:  Hyerim Suh; Krishna Pillai; David Lawson Morris
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

10.  Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer.

Authors:  Ashok K Dilly; Brendon D Honick; Robin Frederick; Anuleka Elapavaluru; Sachin Velankar; Hima Makala; T Kevin Hitchens; Lesley M Foley; Jianxia Guo; Jan H Beumer; Lora Heather Rigatti; Yong J Lee; David L Bartlett; Haroon A Choudry
Journal:  Transl Res       Date:  2020-10-22       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.